A study designed to determine the risk of tumorigenesis after AAV treatment of juvenile/adult mice with ornithine transcarbamylase (OTC) deficiency, which have a high incidence of liver tumors caused by the underlying disease, did not find an increase in tumor formation in the AAV-treated OTC mice.48 The gene discussed is OTC; the disease is neoplasm.